These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23996528)

  • 1. SLAT negatively regulates RANKL-induced osteoclast differentiation.
    Youn BU; Kim K; Kim JH; Lee J; Moon JB; Kim I; Park YW; Kim N
    Mol Cells; 2013 Sep; 36(3):252-7. PubMed ID: 23996528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation.
    Kogawa M; Hisatake K; Atkins GJ; Findlay DM; Enoki Y; Sato T; Gray PC; Kanesaki-Yatsuka Y; Anderson PH; Wada S; Kato N; Fukuda A; Katayama S; Tsujimoto M; Yoda T; Suda T; Okazaki Y; Matsumoto M
    J Biol Chem; 2013 Oct; 288(43):31299-312. PubMed ID: 23990468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
    Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
    Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
    Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
    Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxypeptidase E is a novel modulator of RANKL-induced osteoclast differentiation.
    Kim HJ; Hong J; Yoon HJ; Yoon YR; Kim SY
    Mol Cells; 2014 Sep; 37(9):685-90. PubMed ID: 25220258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
    Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
    J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.
    Franco GC; Kajiya M; Nakanishi T; Ohta K; Rosalen PL; Groppo FC; Ernst CW; Boyesen JL; Bartlett JD; Stashenko P; Taubman MA; Kawai T
    Exp Cell Res; 2011 Jun; 317(10):1454-64. PubMed ID: 21420951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inhibitory effect of vitamin K on RANKL-induced osteoclast differentiation and bone resorption.
    Wu WJ; Kim MS; Ahn BY
    Food Funct; 2015 Oct; 6(10):3351-8. PubMed ID: 26267519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MafB negatively regulates RANKL-mediated osteoclast differentiation.
    Kim K; Kim JH; Lee J; Jin HM; Kook H; Kim KK; Lee SY; Kim N
    Blood; 2007 Apr; 109(8):3253-9. PubMed ID: 17158225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption.
    Kim MS; Day CJ; Selinger CI; Magno CL; Stephens SR; Morrison NA
    J Biol Chem; 2006 Jan; 281(2):1274-85. PubMed ID: 16280328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.
    Song I; Kim JH; Kim K; Jin HM; Youn BU; Kim N
    FEBS Lett; 2009 Jul; 583(14):2435-40. PubMed ID: 19576893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.
    Kim K; Kim JH; Youn BU; Jin HM; Kim N
    J Immunol; 2010 Dec; 185(12):7460-6. PubMed ID: 21068407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
    Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
    BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
    Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
    Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
    Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.